QRXPharma writes off

By Dylan Bushell-Embling
Thursday, 21 August, 2008

QRxPharma (ASX: QRX) has had to write off $18 million in impairment charges this financial year, resulting in a $36 million deficit in the Brisbane-based company's bottom line.

The company accrued $18.1 million in non-cash impairment charges relating to intellectual property licensed from the University of Alabama.

Share based payment charges also accounted for $3.5 million of the deficit.

The remainder of the deficit is in line with QRxPharma's expectations, and has gone towards commercialising the company's Q8004IR dual-opioid oral analgesic, the company said.

The product is expected to be launched in 2010.

Related News

Indigenous-led initiative to resurrect the South Island Giant Moa

New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...

Abnormal brain protein targeted in Parkinson's study

Researchers have identified a new brain protein involved in the development of Parkinson's...

Epilepsy disease model treated in a laboratory dish

A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd